Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elijah J Weber

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Current Opinion in Toxicology|October 24, 2017
Concise Review: Current and Emerging Biomarkers of NephrotoxicityElijah J Weber, Jonathan Himmelfarb, Edward J Kelly
Clinical Pharmacology in Drug Development|February 12, 2024
Evaluation of the Effects of Meal Type and Acid-Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor AgonistElijah J Weber, Islam R Younis, Lulu Wang, et al.
Journal of Clinical Pharmacology|March 7, 2025
Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic-Associated Fatty Liver DiseaseIslam R Younis, Elijah J Weber, Cara Nelson, et al.
Journal of Clinical Pharmacology|March 23, 2024
Pharmacokinetics and Safety of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic ImpairmentIslam R Younis, Cara Nelson, Elijah J Weber, et al.
Clinical Pharmacokinetics|September 18, 2024
Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Firsocostat, a Liver-Targeted Inhibitor of Acetyl-CoA CarboxylaseElijah J Weber, Islam R Younis, Cara Nelson, et al.
Current Protocols in Toxicology|August 5, 2017
Microphysiological Systems to Assess Nonclinical ToxicityKirk P Van Ness, Shih-Yu Chang, Elijah J Weber, et al.
Journal of Clinical Pharmacology|August 30, 2024
Pharmacokinetics and Safety of Cilofexor and Firsocostat in Healthy Japanese and Non-Japanese ParticipantsIslam R Younis, Cara Nelson, Elijah J Weber, et al.
Journal of the American Society of Nephrology : JASN|October 27, 2018
A High-Throughput Screen Identifies DYRK1A Inhibitor ID-8 that Stimulates Human Kidney Tubular Epithelial Cell ProliferationMaria B Monteiro, Susanne Ramm, Vidya Chandrasekaran, et al.
Scientific Reports|October 7, 2018
Technology Transfer of the Microphysiological Systems: A Case Study of the Human Proximal Tubule Tissue ChipCourtney Sakolish, Elijah J Weber, Edward J Kelly, et al.
JCI Insight|December 5, 2017
Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicityShih-Yu Chang, Elijah J Weber, Viktoriya S Sidorenko, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Current Opinion in Toxicology|October 24, 2017
Concise Review: Current and Emerging Biomarkers of NephrotoxicityElijah J Weber, Jonathan Himmelfarb, Edward J Kelly
Clinical Pharmacology in Drug Development|February 12, 2024
Evaluation of the Effects of Meal Type and Acid-Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor AgonistElijah J Weber, Islam R Younis, Lulu Wang, et al.
Journal of Clinical Pharmacology|March 7, 2025
Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic-Associated Fatty Liver DiseaseIslam R Younis, Elijah J Weber, Cara Nelson, et al.
Journal of Clinical Pharmacology|March 23, 2024
Pharmacokinetics and Safety of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic ImpairmentIslam R Younis, Cara Nelson, Elijah J Weber, et al.
Clinical Pharmacokinetics|September 18, 2024
Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Firsocostat, a Liver-Targeted Inhibitor of Acetyl-CoA CarboxylaseElijah J Weber, Islam R Younis, Cara Nelson, et al.
Current Protocols in Toxicology|August 5, 2017
Microphysiological Systems to Assess Nonclinical ToxicityKirk P Van Ness, Shih-Yu Chang, Elijah J Weber, et al.
Journal of Clinical Pharmacology|August 30, 2024
Pharmacokinetics and Safety of Cilofexor and Firsocostat in Healthy Japanese and Non-Japanese ParticipantsIslam R Younis, Cara Nelson, Elijah J Weber, et al.
Journal of the American Society of Nephrology : JASN|October 27, 2018
A High-Throughput Screen Identifies DYRK1A Inhibitor ID-8 that Stimulates Human Kidney Tubular Epithelial Cell ProliferationMaria B Monteiro, Susanne Ramm, Vidya Chandrasekaran, et al.
Scientific Reports|October 7, 2018
Technology Transfer of the Microphysiological Systems: A Case Study of the Human Proximal Tubule Tissue ChipCourtney Sakolish, Elijah J Weber, Edward J Kelly, et al.
JCI Insight|December 5, 2017
Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicityShih-Yu Chang, Elijah J Weber, Viktoriya S Sidorenko, et al.
Pageof 2